Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KZR |
---|---|---|
09:32 ET | 20017 | 0.8099 |
09:34 ET | 8560 | 0.805 |
09:36 ET | 8000 | 0.8 |
09:38 ET | 9493 | 0.8 |
09:39 ET | 32100 | 0.801 |
09:41 ET | 9174 | 0.808 |
09:43 ET | 8006 | 0.81 |
09:45 ET | 14100 | 0.8125 |
09:48 ET | 30292 | 0.8097 |
09:50 ET | 8180 | 0.809 |
09:52 ET | 21258 | 0.80745 |
09:54 ET | 25985 | 0.8061 |
09:56 ET | 3830 | 0.8066 |
09:57 ET | 8200 | 0.79925 |
09:59 ET | 6800 | 0.8012 |
10:01 ET | 7318 | 0.805 |
10:03 ET | 6484 | 0.798 |
10:06 ET | 5826 | 0.809 |
10:08 ET | 7072 | 0.81 |
10:10 ET | 9191 | 0.811 |
10:12 ET | 7274 | 0.815 |
10:14 ET | 26319 | 0.82 |
10:15 ET | 17230 | 0.8162 |
10:17 ET | 9189 | 0.8173 |
10:19 ET | 5602 | 0.815 |
10:21 ET | 22466 | 0.8124 |
10:24 ET | 1980 | 0.812 |
10:26 ET | 4748 | 0.8139 |
10:28 ET | 4900 | 0.8145 |
10:30 ET | 8708 | 0.815 |
10:32 ET | 6600 | 0.8145 |
10:33 ET | 9700 | 0.8122 |
10:35 ET | 4300 | 0.8175 |
10:37 ET | 4001 | 0.8175 |
10:39 ET | 23900 | 0.82 |
10:42 ET | 3100 | 0.8154 |
10:44 ET | 3100 | 0.82 |
10:46 ET | 6906 | 0.81835 |
10:48 ET | 30812 | 0.82 |
10:50 ET | 6500 | 0.82 |
10:51 ET | 8400 | 0.82 |
10:53 ET | 3842 | 0.82 |
10:55 ET | 15173 | 0.8177 |
10:57 ET | 18100 | 0.82 |
11:00 ET | 5929 | 0.8177 |
11:02 ET | 23600 | 0.8177 |
11:04 ET | 4200 | 0.82 |
11:06 ET | 4637 | 0.81885 |
11:08 ET | 4200 | 0.82 |
11:09 ET | 11200 | 0.8205 |
11:11 ET | 10260 | 0.823 |
11:13 ET | 8333 | 0.8183 |
11:15 ET | 12160 | 0.824999 |
11:18 ET | 8900 | 0.8189 |
11:20 ET | 10200 | 0.8217 |
11:22 ET | 15246 | 0.825 |
11:24 ET | 10480 | 0.8277 |
11:26 ET | 8337 | 0.828 |
11:27 ET | 16327 | 0.8254 |
11:29 ET | 15200 | 0.8248 |
11:31 ET | 4922 | 0.8261 |
11:33 ET | 6707 | 0.8247 |
11:36 ET | 11900 | 0.8259 |
11:38 ET | 5508 | 0.82465 |
11:40 ET | 9473 | 0.825 |
11:42 ET | 5140 | 0.82545 |
11:44 ET | 50253 | 0.8291 |
11:45 ET | 34750 | 0.8282 |
11:47 ET | 31630 | 0.83 |
11:49 ET | 14235 | 0.829 |
11:51 ET | 3602 | 0.83 |
11:54 ET | 54846 | 0.8347 |
11:56 ET | 14830 | 0.8342 |
11:58 ET | 13676 | 0.8329 |
12:00 ET | 18918 | 0.835 |
12:02 ET | 4604 | 0.8339 |
12:03 ET | 6327 | 0.835 |
12:05 ET | 18836 | 0.836 |
12:07 ET | 3600 | 0.836 |
12:09 ET | 13067 | 0.8385 |
12:12 ET | 4400 | 0.8375 |
12:14 ET | 25752 | 0.84 |
12:16 ET | 14526 | 0.8366 |
12:18 ET | 4847 | 0.837 |
12:20 ET | 5137 | 0.837 |
12:21 ET | 20510 | 0.83595 |
12:23 ET | 30814 | 0.8368 |
12:25 ET | 3585 | 0.8325 |
12:27 ET | 4900 | 0.8325 |
12:30 ET | 3500 | 0.8325 |
12:32 ET | 3400 | 0.8368 |
12:34 ET | 4661 | 0.8349 |
12:36 ET | 3500 | 0.8349 |
12:38 ET | 16482 | 0.8367 |
12:39 ET | 3700 | 0.8358 |
12:41 ET | 3510 | 0.8334 |
12:43 ET | 11250 | 0.83575 |
12:45 ET | 11517 | 0.8288 |
12:48 ET | 14011 | 0.8271 |
12:50 ET | 4929 | 0.828 |
12:52 ET | 4586 | 0.828 |
12:54 ET | 1200 | 0.83 |
12:56 ET | 4990 | 0.8304 |
12:57 ET | 2000 | 0.8304 |
12:59 ET | 6036 | 0.8309 |
01:01 ET | 4760 | 0.8309 |
01:03 ET | 7300 | 0.8308 |
01:06 ET | 3200 | 0.8308 |
01:08 ET | 3409 | 0.8294 |
01:10 ET | 7222 | 0.8294 |
01:12 ET | 3623 | 0.8294 |
01:14 ET | 5402 | 0.8309 |
01:15 ET | 10815 | 0.8334 |
01:17 ET | 7800 | 0.8307 |
01:19 ET | 6906 | 0.8311 |
01:21 ET | 9800 | 0.8322 |
01:24 ET | 4300 | 0.83215 |
01:26 ET | 5258 | 0.8322 |
01:28 ET | 14800 | 0.8312 |
01:30 ET | 3394 | 0.83215 |
01:32 ET | 4219 | 0.8331 |
01:33 ET | 13260 | 0.8314 |
01:35 ET | 4888 | 0.8312 |
01:37 ET | 9002 | 0.8312 |
01:39 ET | 28065 | 0.81 |
01:42 ET | 7335 | 0.8071 |
01:44 ET | 8300 | 0.81 |
01:46 ET | 4523 | 0.8098 |
01:48 ET | 17732 | 0.8111 |
01:50 ET | 3273 | 0.8112 |
01:51 ET | 4785 | 0.8156 |
01:53 ET | 16568 | 0.80835 |
01:55 ET | 1200 | 0.8072 |
01:57 ET | 3800 | 0.8072 |
02:00 ET | 4200 | 0.80835 |
02:02 ET | 1400 | 0.8096 |
02:04 ET | 6200 | 0.815 |
02:06 ET | 6410 | 0.8155 |
02:08 ET | 6700 | 0.8155 |
02:09 ET | 7244 | 0.8199 |
02:11 ET | 9700 | 0.818 |
02:13 ET | 5900 | 0.8115 |
02:15 ET | 3200 | 0.8132 |
02:18 ET | 6000 | 0.8149 |
02:20 ET | 8300 | 0.8124 |
02:22 ET | 7244 | 0.8123 |
02:24 ET | 3071 | 0.8137 |
02:26 ET | 4600 | 0.815 |
02:27 ET | 6740 | 0.8142 |
02:29 ET | 2944 | 0.8158 |
02:31 ET | 5300 | 0.8155 |
02:33 ET | 5083 | 0.82 |
02:36 ET | 6692 | 0.825 |
02:38 ET | 6430 | 0.8249 |
02:40 ET | 6556 | 0.8235 |
02:42 ET | 4472 | 0.8181 |
02:44 ET | 7098 | 0.82465 |
02:45 ET | 6278 | 0.8274 |
02:47 ET | 7408 | 0.8333 |
02:49 ET | 9400 | 0.8282 |
02:51 ET | 8938 | 0.827 |
02:54 ET | 9699 | 0.8259 |
02:56 ET | 19909 | 0.8299 |
02:58 ET | 5308 | 0.8299 |
03:00 ET | 5865 | 0.829 |
03:02 ET | 6015 | 0.8269 |
03:03 ET | 7850 | 0.83 |
03:05 ET | 5642 | 0.8241 |
03:07 ET | 5418 | 0.8257 |
03:09 ET | 8110 | 0.82735 |
03:12 ET | 6800 | 0.8285 |
03:14 ET | 8113 | 0.8285 |
03:16 ET | 5851 | 0.82705 |
03:18 ET | 13324 | 0.83 |
03:20 ET | 7100 | 0.8269 |
03:21 ET | 8900 | 0.8157 |
03:23 ET | 11500 | 0.8181 |
03:25 ET | 6750 | 0.816 |
03:27 ET | 5755 | 0.82 |
03:30 ET | 7100 | 0.8231 |
03:32 ET | 12519 | 0.8209 |
03:34 ET | 8100 | 0.8183 |
03:36 ET | 9300 | 0.8235 |
03:38 ET | 8200 | 0.8185 |
03:39 ET | 6485 | 0.82 |
03:41 ET | 18118 | 0.8189 |
03:43 ET | 12400 | 0.8195 |
03:45 ET | 8912 | 0.8238 |
03:48 ET | 16701 | 0.8238 |
03:50 ET | 11500 | 0.825 |
03:52 ET | 13614 | 0.8222 |
03:54 ET | 13491 | 0.8264 |
03:56 ET | 18715 | 0.8289 |
03:57 ET | 18599 | 0.8283 |
03:59 ET | 41186 | 0.83 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kezar Life Sciences Inc | 57.7M | -0.6x | --- |
Kronos Bio Inc | 59.1M | -0.6x | --- |
LAVA Therapeutics NV | 43.9M | -1.9x | --- |
Affimed NV | 50.4M | -0.6x | --- |
BioLine RX Ltd | 48.7M | -0.7x | --- |
Cue Biopharma Inc | 43.3M | -0.8x | --- |
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $57.7M |
---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 73.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.21 |
EPS | $-1.35 |
Book Value | $2.58 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 8.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,531.57% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.